<p>Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European Countries</p>-Reference-Cited by-同舟云学术

Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European Countries

Published:2020-05 Issue: Volume:Volume 12 Page:423-433
ISSN:1179-1349
Container-title:Clinical Epidemiology
language:en
Short-container-title:CLEP

Author:

Heintjes Edith^ORCID,Bezemer Irene D,Prieto-Alhambra Daniel,Smits Elisabeth,Booth Helen P,Dedman Daniel^ORCID,He Ying,Hoti Fabian,Vehkala Minna,de Vogel Stefan,Robinson Noah Jamie,Appenteng Kwame,Penning-van Beest Fernie JA

Publisher

Informa UK Limited

Subject

Epidemiology

Reference30 articles.

1. A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study)

2. Estudio observacional retrospectivo multicéntrico de pacientes con vejiga hiperactiva en tratamiento con mirabegrón y oxibutinina en condiciones de práctica clínica habitual

3. Effectiveness of antiplatelet therapy in atherosclerotic disease: comparing the ASA low-response prevalence in CVD, CAD and PAD

4. Guideline on Good Pharmacovigilance Practices (GVP) - Module IX – Signal Management (Rev 1). Vol. 2017. European Medicines Agency and Heads of Medicines Agencies; 2017.

5. Drug utilization study of mirabegron (Betmiga®) using real-world healthcare databases from the Netherlands. EU PAS Register Number 15063. Spain, UK and Finland. 2017. Available from: http://www.encepp.eu/encepp/viewResource.htm?id=29595. Accessed March 13, 2020.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pooling of primary care electronic health record (EHR) data on Huntington’s disease (HD) and cancer: establishing comparability of two large UK databases;BMJ Open;2024-02

2. Regular use of proton-pump inhibitors and risk of stroke: a population-based cohort study and meta-analysis of randomized-controlled trials;BMC Medicine;2021-12

3. Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study;Drug Safety;2021-07-08

4. Long-term effectiveness of an intervention to enhance mirabegron use revision and its deprescribing: 36-month follow-up of a quasi-experimental trial in primary care;Current Medical Research and Opinion;2021-02-26